Trial Profile
A prospective, multicentre trial evaluated efficacy and safety of switching antiretroviral therapy to abacavir/lamivudine (Kivexa) plus rilpivirine or to Emtricitabine/rilpivirine/tenofovir-disoproxil-fumarate (Eviplera) in HIV infected patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Mar 2016
Price :
$35
*
At a glance
- Drugs Lamivudine/abacavir (Primary) ; Rilpivirine (Primary) ; Emtricitabine/rilpivirine/tenofovir disoproxil fumarate
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- 03 Mar 2016 New trial record